Literature DB >> 14501841

Cardiomyopathy in muscular dystrophies.

Francesco Muntoni1.   

Abstract

PURPOSE OF REVIEW: The association of cardiac complications in patients with muscular dystrophies has been known for a long time. However, until recently, the clinical and genetic heterogeneity of these conditions had hampered our abilities to recognize individual disease complications, especially in the rarer forms. Over the years the improved understanding of the molecular defects responsible for several of these forms has also allowed recognition of the associated cardiac complications. RECENT
FINDINGS: There have been significant new findings regarding the understanding of the type, progression and pathogenesis of the cardiac involvement found in a number of muscular dystrophies. The natural history of cardiac involvement in Emery-Dreifuss muscular dystrophy was described in detail by different studies. Novel non-invasive techniques to assess early cardiac involvement were reported in patients with Duchenne and Becker muscular dystrophies; improved understanding of the pattern and pathogenesis of cardiac involvement of sarcoglycanopathies was reported, together with the description of the cardiac involvement in forms of limb girdle muscular dystrophies secondary to abnormal glycosylation. Therapeutic intervention strategies for each individual condition were also proposed.
SUMMARY: Our understanding of the incidence, type and pathogenesis of the molecular basis for cardiac involvement in different muscular dystrophies has improved significantly over the last year. This has resulted in the proposal of novel therapeutic guidelines that will help the management of patients with muscular dystrophies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501841     DOI: 10.1097/01.wco.0000093100.34793.81

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  32 in total

1.  Late gadolinium enhanced cardiovascular magnetic resonance in Becker muscular dystrophy.

Authors:  A Varghese; D J Pennell
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

2.  Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments.

Authors:  Carmen Vitiello; Stefania Faraso; Nicolina Cristina Sorrentino; Giovanni Di Salvo; Edoardo Nusco; Gerardo Nigro; Luisa Cutillo; Raffaele Calabrò; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

Review 3.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

4.  Multiscale models of skeletal muscle reveal the complex effects of muscular dystrophy on tissue mechanics and damage susceptibility.

Authors:  Kelley M Virgilio; Kyle S Martin; Shayn M Peirce; Silvia S Blemker
Journal:  Interface Focus       Date:  2015-04-06       Impact factor: 3.906

5.  Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.

Authors:  Debra A O'Leary; Orzala Sharif; Paul Anderson; Buu Tu; Genevieve Welch; Yingyao Zhou; Jeremy S Caldwell; Ingo H Engels; Achim Brinker
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

Review 6.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

Review 7.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

8.  Current treatment and management of dystrophinopathies.

Authors:  Nathalie Goemans; Gunnar Buyse
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

9.  Proteomic Profiling of the Dystrophin-Deficient MDX Heart Reveals Drastically Altered Levels of Key Metabolic and Contractile Proteins.

Authors:  Caroline Lewis; Harald Jockusch; Kay Ohlendieck
Journal:  J Biomed Biotechnol       Date:  2010-05-23

Review 10.  Clinical practice: heart failure in children. Part I: clinical evaluation, diagnostic testing, and initial medical management.

Authors:  Paul F Kantor; Luc L Mertens
Journal:  Eur J Pediatr       Date:  2009-08-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.